Wednesday, July 8, 2026

Drug profile · INN

ethionamide

ethionamide (TRECATOR) is a enoyl-[acyl-carrier-protein] reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ethionamide
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

ethionamide (TRECATOR) is a enoyl-[acyl-carrier-protein] reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ethionamide
Brand TRECATOR
Mechanism Enoyl-[acyl-carrier-protein] reductase inhibitor
Target Enoyl-[acyl-carrier-protein] reductase [NADH]
Route ORAL
Formulation TABLET

Mechanism of action

Enoyl-[acyl-carrier-protein] reductase inhibitor

Primary target: Enoyl-[acyl-carrier-protein] reductase [NADH]

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. hexachlorophene Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
  2. isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor

Frequently asked questions

What is ethionamide?

ethionamide (TRECATOR) is a enoyl-[acyl-carrier-protein] reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ethionamide?

TRECATOR is a marketed brand name for ethionamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ethionamide?

ethionamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.